The present invention relates to a cell therapy method for treating neurodegenerative diseases, which includes administering a therapeutically effective amount of a regulatory T cell to an individual in need thereof. The regulatory T cell may be an amyloid-beta specific regulatory T cell induced by administering amyloid-beta peptide and bee venom phospholipase A2 (bvPLA2).